---
title: "Cryoport surges 8%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304875700.md"
description: "Cryoport rose 7.59% to US$20.55. Up 51.10% over six months and up 114.06% YTD."
datetime: "2026-11-09T20:29:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304875700.md)
  - [en](https://longbridge.com/en/news/304875700.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304875700.md)
generator: "portal-rs"
---

# Cryoport surges 8%

Cryoport (CYRX.US) surged nearly **8%** during regular trading to **$20.55**.

The stock is up 26.62% over the past five sessions, up 51.10% over the past six months and up 114.06% year to date. It sits 170.04% above its 52-week low of US$7.610. The intraday swing reached 10.47%.

The Nasdaq Composite is up 0.74% over the past five sessions and up 9.07% year to date.

The life sciences tools and services industry index rose 3.7% over the same period.

The company reported fiscal third-quarter revenue of $50.2 million, up 14% from a year earlier and topping the analyst consensus of $48.8 million. Adjusted EBITDA came in at $1.1 million, turning positive and exceeding the estimate of $551,000. Cryoport raised its full-year 2026 revenue guidance to $197 million to $199 million.

Net loss for the quarter widened 56% year-over-year to $10.9 million. Revenue from commercial cell and gene therapy grew 20%, while life sciences services revenue rose 18% to $28.56 million. During the quarter, the company supported 788 global clinical trials and 23 approved cell and gene therapies.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [CYRX.US](https://longbridge.com/en/quote/CYRX.US.md)

## Related News & Research

- [CryoPort (NASDAQ:CYRX) Stock: Insider Daniel Hancock Sells 74,379 Shares](https://longbridge.com/en/news/305449778.md)
- [Cryoport (CYRX) Lifts 2026 Outlook Following Revenue Update As Fair Value Stays Just Behind](https://longbridge.com/en/news/304925527.md)
- [AI solves 167-year-old maths problem, Anthropic researcher claims](https://longbridge.com/en/news/306318851.md)
- [Marvell Stock’s (MRVL) Plunge Is My Opportunity to Buy](https://longbridge.com/en/news/306273400.md)
- [Lumentum President of Global Business Units Wupen Yuen Reports Sale of $833,200 in Common Shares](https://longbridge.com/en/news/306338831.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**